相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Discovery of acquired molecular signature on immune checkpoint inhibitors in paired tumor tissues
Shin Hye Yoo et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2021)
Molecular biology of Hodgkin lymphoma
Marc A. Weniger et al.
LEUKEMIA (2021)
Relatlimab (RELA) plus nivolumab (NIVO) versus NIVO in first-line advanced melanoma: Primary phase III results from RELATIVITY-047 (CA224-047).
Evan J. Lipson et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
LAG-3 is expressed on a majority of tumor infiltrating lymphocytes in pediatric Hodgkin lymphoma
Scott Moerdler et al.
LEUKEMIA & LYMPHOMA (2021)
KEYNOTE-013 4-year follow-up of pembrolizumab in classical Hodgkin lymphoma after brentuximab vedotin failure
Philippe Armand et al.
BLOOD ADVANCES (2020)
Influence of tumor-associated macrophages and HLA class I expression according to HPV status in head and neck cancer patients receiving chemo/bioradiotherapy
Dan Ou et al.
RADIOTHERAPY AND ONCOLOGY (2019)
Optimizing checkpoint inhibitors therapy for relapsed or progressive classic Hodgkin lymphoma by multiplex immunohistochemistry of the tumor microenvironment
Antonino Carbone et al.
CANCER MEDICINE (2019)
Characterization of a novel anti-human lymphocyte activation gene 3 (LAG-3) antibody for cancer immunotherapy
Xiaojie Yu et al.
MABS (2019)
Pembrolizumab in relapsed or refractory Hodgkin lymphoma: 2-year follow-up of KEYNOTE-087
Robert Chen et al.
BLOOD (2019)
The microenvironmental niche in classic Hodgkin lymphoma is enriched for CTLA-4-positive T cells that are PD-1-negative
Sanjay S. Patel et al.
BLOOD (2019)
Fibrinogen-like Protein 1 Is a Major Immune Inhibitory Ligand of LAG-3
Jun Wang et al.
CELL (2019)
Programmed cell death protein-1 (PD1) expression in the microenvironment of classical Hodgkin lymphoma is similar between favorable and adverse outcome and does not enrich over serial relapses with conventional chemotherapy
Joseph G. Taylor et al.
HAEMATOLOGICA (2019)
Programmed cell death protein1 (PD1)-expression in the microenvironment of classical Hodgkin lymphoma at relapse after conventional chemotherapy and at relapse on anti-PD1 treatment
Stephanie Sasse et al.
HAEMATOLOGICA (2019)
Mass cytometry of Hodgkin lymphoma reveals a CD4+ regulatory T-cell-rich and exhausted T-effector microenvironment
Fathima Zumla Cader et al.
BLOOD (2018)
Nivolumab for Relapsed/Refractory Classic Hodgkin Lymphoma After Failure of Autologous Hematopoietic Cell Transplantation: Extended Follow-Up of the Multicohort Single-Arm Phase II CheckMate 205 Trial
Philippe Armand et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Challenges and perspectives in the immunotherapy of Hodgkin lymphoma
Jean-Marie Michot et al.
EUROPEAN JOURNAL OF CANCER (2017)
LAG3 (CD223) as a cancer immunotherapy target
Lawrence P. Andrews et al.
IMMUNOLOGICAL REVIEWS (2017)
Tumour-associated macrophages as treatment targets in oncology
Alberto Mantovani et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2017)
Topological analysis reveals a PD-L1-associated microenvironmental niche for Reed-Sternberg cells in Hodgkin lymphoma
Christopher D. Carey et al.
BLOOD (2017)
Coinhibitory Pathways in Immunotherapy for Cancer
Susanne H. Baumeister et al.
ANNUAL REVIEW OF IMMUNOLOGY, VOL 34 (2016)
The 2016 revision of the World Health Organization classification of lymphoid neoplasms
Steven H. Swerdlow et al.
BLOOD (2016)
PD-L1 and PD-L2 Genetic Alterations Define Classical Hodgkin Lymphoma and Predict Outcome
Margaretha G. M. Roemer et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Coexpression of CD49b and LAG-3 identifies human and mouse T regulatory type 1 cells
Nicola Gagliani et al.
NATURE MEDICINE (2013)
Immune Inhibitory Molecules LAG-3 and PD-1 Synergistically Regulate T-cell Function to Promote Tumoral Immune Escape
Seng-Ryong Woo et al.
CANCER RESEARCH (2012)
MHC Class II Engagement by Its Ligand LAG-3 (CD223) Contributes to Melanoma Resistance to Apoptosis
Patrice Hemon et al.
JOURNAL OF IMMUNOLOGY (2011)
Negative regulation of T cell homeostasisby lymphocyte activation gene-3 (CD223)
CJ Workman et al.
JOURNAL OF IMMUNOLOGY (2005)
Biochemical analysis of the regulatory T cell protein lymphocyte activation gene-3 (LAG-3; CD223)
NY Li et al.
JOURNAL OF IMMUNOLOGY (2004)
分享论文
